Evidence map›Paper›PMID 35310914›Full record

ReviewJournal of oncology2022

Aldehyde Dehydrogenase 1 in Gastric Cancer.

Ling Wang, Luosha Wang, Yang Yu, Ruiliang Su, Yating Zhang, Yumin Li, Mingde Zang

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Mechanisms of chemoresistance in gastric cancer: interplay between microRNAs and the tumor microenvironment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Review
  4. Article
  5. Multiple roles of ALDH1 in health and disease.Frontiers in physiology · 2025
    Review
  6. The Significance of Aldehyde Dehydrogenase 1 in Cancers.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ling Wang *Department of Gastric Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Luosha Wang *Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Yang YuLanzhou University Second Hospital, Lanzhou, Gansu, China.
Ruiliang SuLanzhou University Second Hospital, Lanzhou, Gansu, China.
Yating ZhangLanzhou University Second Hospital, Lanzhou, Gansu, China.
Yumin LiLanzhou University Second Hospital, Lanzhou, Gansu, China.ORCID https://orcid.org/0000-0002-9267-1412
Mingde ZangDepartment of Gastric Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0000-0001-7073-3195
Lanzhou University Second Hospital · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is a disease that threatens human health. It is thus crucial to clarify the mechanisms involved in GC development and discover diagnostic biomarkers and therapeutics. As a cancer stem cell marker, aldehyde dehydrogenase 1 (ALDH1) is involved in the development, progression, and treatment of GC. This review evaluated the prognostic value of ALDH1 and explored its mechanism of action in GC. Importantly, ALDH1 is an informative biomarker in clinical practice as it has specific relationships with indicators, such as metastasis and overall survival. Additionally, ALDH1 interacts with genes and exhibits properties that mimic stem cell characteristics amongst other mechanisms employed in the occurrence and progression of GC. Our results, therefore, provide evidence of possible clinical utility of ALDH1 as a GC therapeutic target.

Identifiers

PMID35310914
PMCPMC8926486
OpenAlexW4221057347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.